Ergomed Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

Ergomed (LON:ERGO) Full Year 2022 Results

Key Financial Results

• Revenue: UK£145.3m (up 23% from FY 2021).
• Net income: UK£15.0m (up 18% from FY 2021).
• Profit margin: 10% (in line with FY 2021).
• EPS: UK£0.30 (up from UK£0.26 in FY 2021).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ergomed Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) missed analyst estimates by 12%.

Looking ahead, revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom.

Performance of the British Life Sciences industry.

The company's shares are down 6.6% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Ergomed you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.